Correlation Between Bristol Myers and MaxCyte

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Bristol Myers and MaxCyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and MaxCyte into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Bristol Myers Squibb and MaxCyte, you can compare the effects of market volatilities on Bristol Myers and MaxCyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of MaxCyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and MaxCyte.

Diversification Opportunities for Bristol Myers and MaxCyte

-0.8
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Bristol and MaxCyte is -0.8. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and MaxCyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on MaxCyte and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with MaxCyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of MaxCyte has no effect on the direction of Bristol Myers i.e., Bristol Myers and MaxCyte go up and down completely randomly.

Pair Corralation between Bristol Myers and MaxCyte

Considering the 90-day investment horizon Bristol Myers Squibb is expected to generate 0.55 times more return on investment than MaxCyte. However, Bristol Myers Squibb is 1.83 times less risky than MaxCyte. It trades about 0.06 of its potential returns per unit of risk. MaxCyte is currently generating about -0.02 per unit of risk. If you would invest  4,887  in Bristol Myers Squibb on August 27, 2024 and sell it today you would earn a total of  1,000.00  from holding Bristol Myers Squibb or generate 20.46% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Bristol Myers Squibb  vs.  MaxCyte

 Performance 
       Timeline  
Bristol Myers Squibb 

Risk-Adjusted Performance

13 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak primary indicators, Bristol Myers showed solid returns over the last few months and may actually be approaching a breakup point.
MaxCyte 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days MaxCyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Bristol Myers and MaxCyte Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Bristol Myers and MaxCyte

The main advantage of trading using opposite Bristol Myers and MaxCyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, MaxCyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MaxCyte will offset losses from the drop in MaxCyte's long position.
The idea behind Bristol Myers Squibb and MaxCyte pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Complementary Tools

Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments